FDA's Social Media Insight - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

FDA's Social Media Insight
Guidance offered on how to deal with off-label information requests.

Pharmaceutical Technology
Volume 36, Issue 2, pp. 12

Stephanie Sutton
Dedicated social media recommendations from FDA may not yet have materialized, but the agency is beginning to address some of the industry's questions in this area. At the end of 2011, FDA released a draft guidance titled Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices, which includes recommendations on responding through online channels such as forums and chat rooms.

According to the guidance, many firms encounter requests for off-label information about their products through websites, discussion boards, and other electronic forums, and FDA recognizes that firms are capable of responding to such requests in a "truthful, non-misleading, and accurate manner." Indeed, FDA acknowledges that it can be in the best interest of public health for companies to reply to these requests because other participants in the discussion may not be able to provide accurate information.

The guidance discusses responses to both non-public information requests, such as a one-on-one email or telephone call, and public requests, such as a request on an online forum. The latter type is more complicated because firms must ensure that their response does not communicate unapproved information to those who have not asked for it.

If a firm responds to unsolicited requests for off-label information in the manner described in the draft guidance, FDA said it will not use such responses as evidence of a firm's intent that the product be used for unapproved or cleared uses.

Stephanie Sutton is an associate editor of Pharmaceutical Technology.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here